149 related articles for article (PubMed ID: 29417642)
1. Carvacrol induces cytotoxicity in human cervical cancer cells but causes cisplatin resistance: Involvement of MEK-ERK activation.
Potočnjak I; Gobin I; Domitrović R
Phytother Res; 2018 Jun; 32(6):1090-1097. PubMed ID: 29417642
[TBL] [Abstract][Full Text] [Related]
2. Carvacrol attenuates acute kidney injury induced by cisplatin through suppression of ERK and PI3K/Akt activation.
Potočnjak I; Domitrović R
Food Chem Toxicol; 2016 Dec; 98(Pt B):251-261. PubMed ID: 27825756
[TBL] [Abstract][Full Text] [Related]
3. Oleanolic acid attenuates cisplatin-induced nephrotoxicity in mice and chemosensitizes human cervical cancer cells to cisplatin cytotoxicity.
Potočnjak I; Šimić L; Vukelić I; Domitrović R
Food Chem Toxicol; 2019 Oct; 132():110676. PubMed ID: 31306688
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C β inhibits autophagy and sensitizes cervical cancer Hela cells to cisplatin.
Li N; Zhang W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28246354
[TBL] [Abstract][Full Text] [Related]
5. DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells.
Watanabe M; Naraba H; Sakyo T; Kitagawa T
Mol Cancer Res; 2010 Nov; 8(11):1547-57. PubMed ID: 20870738
[TBL] [Abstract][Full Text] [Related]
6. Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta.
Basu A; Tu H
Biochem Biophys Res Commun; 2005 Sep; 334(4):1068-73. PubMed ID: 16039614
[TBL] [Abstract][Full Text] [Related]
7. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
8. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway.
Ma H; Han F; Yan X; Qi G; Li Y; Li R; Yan S; Yuan C; Song K; Kong B
J Cell Physiol; 2021 Apr; 236(4):2767-2781. PubMed ID: 33184870
[TBL] [Abstract][Full Text] [Related]
9. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
11. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
12. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
[TBL] [Abstract][Full Text] [Related]
13. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
14. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion.
Chen WL; Barszczyk A; Turlova E; Deurloo M; Liu B; Yang BB; Rutka JT; Feng ZP; Sun HS
Oncotarget; 2015 Jun; 6(18):16321-40. PubMed ID: 25965832
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1.
Mohanty S; Huang J; Basu A
Clin Cancer Res; 2005 Sep; 11(18):6730-7. PubMed ID: 16166454
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin.
Dhar R; Basu A
Int J Oncol; 2008 May; 32(5):1133-7. PubMed ID: 18425342
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
[TBL] [Abstract][Full Text] [Related]
19. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.
Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH
Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
